右美托咪定滴鼻联合舒芬太尼在儿童肿瘤放射治疗中的应用研究

目的:比较右美托咪定滴鼻联合舒芬太尼和单独使用水合氯醛在儿童肿瘤放射治疗过程中的疗效。方法:选取2018年11月至2019年9月深圳市人民医院行肿瘤放疗的48例患儿作为研究对象,随机分组为接受右美托咪定滴鼻联合舒芬太尼组(DS组)和口服水合氯醛组(C组)。观察比较两组镇静起效时间、苏醒时间和放射治疗时间,以及镇静前后平均动脉血压(MAP)、心率(HR)和血氧饱和度(SpO2)的变化情况,并统计两组不良反应发生情况。结果:研究纳入48例患儿,其中DS组24例和C组23例纳入最终分析。与C组相比,DS组患儿恢复时间更短,MAP、HR和不良反应发生率更低。两组患儿用药起效时间、治疗时间的差异无统计学意义(P>0.05)。结论:右美托咪定滴鼻联合舒芬太尼能安全地应用于儿童肿瘤放射治疗并缩短恢复时间。

Comparison of the effects of dexmedetomidine and sufentanil combination and chloral hydrate in pediatric patients during tumor radiotherapy: a randomized controlled trial

  Objective  To compare the effects of dexmedetomidine and sufentanil (DS) combination and chloral hydrate (C) alone in pediatric patients during tumor radiotherapy.  Methods  In total, 48 children treated with radiotherapy at Shenzhen People's Hospital from November 2018 to September 2019 were enrolled in this study. Changes in sedation onset, recovery, and radiation treatment time and those in mean arterial blood pressure (MAP), heart rate (HR) and oxygen saturation (SpO₂) after sedation, and incidence of adverse reactions were recorded.  Results  Overall, 48 patients (24 in Group DS and 23 in Group C) were ultimately included in the analysis after enrollment. Patients in Group DS had shorter recovery time and lower MAP, HR, and incidence of adverse reactions than those in Group C. The onset and treatment time did not significantly differ between the two groups.  Conclusions  The use of the combination of dexmedetomidine and sufentanil was safe for pediatric patients during tumor radiotherapy and reduced recovery time.